|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-8-21
|
|
pubmed:abstractText |
We investigated the effect of the proinflammatory cytokine interleukin 17 (IL-17) on the lysis of osteosarcoma cells by human NK cells. NK cells and U-2 OS, MG-63, HOS osteosarcoma cell lines express the IL-17 receptor, the highest amount being found on U-2 OS. Pre-incubation of NK cells with IL-17 did not affect the cytotoxicity against osteosarcomas, that was increased when U-2 OS were pre-incubated with IL-17. In IL-17 treated U-2 OS osteosarcoma cells FACS analysis demonstrated an increased expression of fibronectin among the panel of adhesion molecules assayed, and the treatment with anti-fibronectin antibodies decreased the NK cytotoxicity. The comparison between interferon gamma (IFN-gamma) treated and IFN-gamma/IL-17-treated U-2 OS showed a decreased susceptibility to NK lysis associated with a reduced expression of CD49f on U-2 OS treated with IFN-gamma/IL-17. IL-17 appears to be a modulator of NK adhesion molecules on U-2 OS cells but antagonizes with IFN-gamma on NK lysis.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-10446984,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-10536172,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-10781900,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-11062734,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-11083268,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-11687452,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-11877287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-11907081,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-11923115,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-12059115,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-12411307,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-1622136,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-3263421,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-6403616,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-7499828,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-7506724,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-7873286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-8542943,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-8992882,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-9109391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-9367539,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-9470825,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-9531313,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12930359-9886425
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Fibronectins,
http://linkedlifedata.com/resource/pubmed/chemical/IL17RA protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin alpha2,
http://linkedlifedata.com/resource/pubmed/chemical/Integrin alpha6,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-17,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-17,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0009-9104
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
133
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
344-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12930359-Adult,
pubmed-meshheading:12930359-Bone Neoplasms,
pubmed-meshheading:12930359-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:12930359-Fibronectins,
pubmed-meshheading:12930359-Flow Cytometry,
pubmed-meshheading:12930359-Humans,
pubmed-meshheading:12930359-Integrin alpha2,
pubmed-meshheading:12930359-Integrin alpha6,
pubmed-meshheading:12930359-Interferon-gamma,
pubmed-meshheading:12930359-Interleukin-17,
pubmed-meshheading:12930359-Killer Cells, Natural,
pubmed-meshheading:12930359-Osteosarcoma,
pubmed-meshheading:12930359-Receptors, Interleukin,
pubmed-meshheading:12930359-Receptors, Interleukin-17,
pubmed-meshheading:12930359-Recombinant Proteins,
pubmed-meshheading:12930359-Stimulation, Chemical,
pubmed-meshheading:12930359-Tumor Cells, Cultured
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis.
|
|
pubmed:affiliation |
Laboratorio di Immunologia e Genetica, Istituti Ortopedici Rizzoli, Via di Barbiano 1/10, 40136 Bologna, Italy. labimge@alma.unibo.it
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
